Sonnet BioTherapeutics Holdings, Inc. (SONN)
|Net Income (ttm)||-65.60M|
|Trading Day||January 21|
|Day's Range||2.62 - 2.73|
|52-Week Range||0.34 - 7.99|
Wall Street recommends buying shares of Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) and Sigma Labs Inc. (NASDAQ:SGLB), which you would not expect after these 2 stocks performed so poorl...
PRINCETON, NJ / ACCESSWIRE / December 17, 2020 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted bio...
The pandemic highlights how far medical science has come. It also highlights how exciting the future is.
Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the ...
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) were down 11% on Wednesday after skyrocketing 56.9% on Tuesday on COVID-19-related news.
Sonnet BioTherapeutics Holdings, an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neur... [Read more...]
|Stock Exchange |
|Ticker Symbol |